Martell Bridget A
SEC-identified person · CIK 1629627 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Aligos Therapeutics, Inc. ALGS | Director | filed 2021 - 2026 |
| Delcath Systems, INC. DTCH | Director | filed 2024 - 2026 |
| Sonus Pharmaceuticals INC ogxi | Director | filed 2021 - 2025 |
| Ayala Pharmaceuticals, Inc. ADXS | Director | filed 2023 - 2023 |
| Old Ayala, Inc AYLA | Director | filed 2023 - 2023 |
| Therapeutics Acquisition Corp. TXAC | Director | filed 2023 - 2023 |
| Zeta Acquisition Corp III KURO | Acting Chief Medical Officer | filed 2020 - 2020 |
| Juniper Pharmaceuticals INC cbrx | Chief Medical Officer | filed 2015 - 2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.